| Unknown | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung A NCT04459078 | Hunan Cancer Hospital | Phase 2 |
| Withdrawn | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung NCT02466568 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Met NCT04046614 | AIO-Studien-gGmbH | Phase 1 / Phase 2 |
| Terminated | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary NCT03041181 | Nasser Hanna, M.D. | Phase 2 |
| Terminated | Circulating Tumor DNA in Patients at High Risk for Lung Cancer NCT02715102 | Pathway Genomics | — |
| Completed | Icotinib for Completed Resected IB NSCLC With EGFR Mutation NCT02264210 | Sun Yat-sen University | Phase 2 |
| Unknown | Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer NCT02288026 | Capital Medical University | — |
| Unknown | Telomere Biology in Early Adenocarcinoma of the Lung NCT02239432 | Meir Medical Center | — |
| Terminated | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung C NCT02134912 | SWOG Cancer Research Network | Phase 2 |
| Completed | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell NCT01958372 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Withdrawn | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC NCT02059967 | Virginia Commonwealth University | Phase 1 |
| Completed | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers NCT01935336 | University of Colorado, Denver | Phase 2 |
| Completed | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorect NCT01726296 | Fox Chase Cancer Center | N/A |
| Terminated | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer NCT01707823 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Completed | Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung NCT01561456 | Axelar AB | Phase 2 |
| Completed | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung NCT01218516 | Morphotek | Phase 2 |
| Completed | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung NCT01259089 | Northwestern University | Phase 1 / Phase 2 |
| Active Not Recruiting | Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination NCT01345851 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008 NCT00511485 | Endocyte | Phase 2 |
| Completed | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage NCT01557959 | Wake Forest University Health Sciences | Phase 2 |
| Completed | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell L NCT00368992 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Adv NCT00369551 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Sta NCT00118183 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer NCT00118144 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer NCT00087412 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Photodynamic Therapy in Treating Patients With Lung Cancer NCT01668823 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Remov NCT00049543 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurr NCT00021060 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III N NCT00042835 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell NCT00040794 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III N NCT00020709 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non NCT00005838 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer NCT00002852 | National Cancer Institute (NCI) | Phase 3 |